# Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

> **NCT02898454** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 448 (actual)

## Conditions studied

- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

## Interventions

- **DRUG:** Dupilumab SAR231893 (REGN668)
- **DRUG:** Placebo
- **DRUG:** Mometasone furoate nasal spray

## Key facts

- **NCT ID:** NCT02898454
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-28
- **Primary completion:** 2018-08-27
- **Final completion:** 2018-11-16
- **Target enrollment:** 448 (ACTUAL)
- **Last updated:** 2019-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02898454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02898454, "Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02898454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*